Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rhTNK-tPA vs Tirofiban in STEMI with High Thrombus Burden
NCT06769256Phase 4Recruiting
- Sponsor
- Henan Institute of Cardiovascular Epidemiology
- Start
- Jan 2025
- Primary completion
- Dec 2027
- Modality
- rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
A Phase 4 trial of tenecteplase in ST-segment elevation myocardial infarction (STEMI), sponsored by Henan Institute of Cardiovascular Epidemiology. Started Jan 2025; status: recruiting.
02
Drugs
tenecteplase
03
Conditions
ST-segment elevation myocardial infarction (STEMI)
Beyond the preview
Go deeper on NCT06769256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06769256.